Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Biotin→

Biotin Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
58-85-5
Molecular formula
C10H16N2O3S
Molecular weight
244.31 g/mol
Drug class
Water-soluble vitamin B7coenzyme for carboxylase enzymes
Mechanism of action
Functions as a covalently bound cofactor for acetyl-CoA carboxylase, pyruvate carboxylase, propionyl-CoA carboxylase and 3-methylcrotonyl-CoA carboxylase, supporting fatty-acid synthesis, gluconeogenesis and amino-acid catabolism.
Indications / reported uses
  • Prevention and treatment of biotin deficiency, including deficiency due to inherited biotinidase or holocarboxylase synthetase disorders under specialist care
  • Routine supplementation when dietary intake or absorption is inadequate; evidence does not support treating hair loss or brittle nails in the absence of deficiency

Sources: NIH Office of Dietary Supplements — Biotin fact sheet · NLM MedlinePlus — Biotin · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Biotin Environmental Risk Assessment (ERA) (the Biotin ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.